McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report.
OBJECTIVE
The use of drug therapy based on cabergoline, octreotide and long-acting release (LAR) octreotide has presented varying results in the treatment of GH excessive production in patients with McCune-Albright Syndrome.


METHODS
We report the case of a 29 year-old female patient presenting McCune-Albright Syndrome and complaint of excessive bone growth.


RESULTS
The patient presented a pituitary adenoma involving the right internal carotid artery and excessive secretion of growth hormone (no GH suppression was observed after the oral glucose tolerance test). Due to the presence of diffuse thickness in skull base bones, surgical approach was not considered effective and the patient was submitted to drug therapy with octreotide LAR and cabergoline. At the one year follow-up, GH and IGF-1 levels were normal and no adverse effects were present.


CONCLUSIONS
The use of drug therapy based on the association of cabergoline and octreotide is safe and able to achieve complete hormonal control in the treatment of acromegaly for McCune-Albright patients.
Department of Neuroendocrinology, Hospital Geral de Fortaleza,Universidade Federal do Ceará (UFCE), Medical School, Fortaleza, CE, Brazil. jpaulocavalcante@yahoo.com.br
João Paulo C
JP
Almeida
Lucas Alverne F
LA
Albuquerque
Camila L H
CL
Ferraz
Italo
I
Mota
Jackson
J
Gondim
Tânia M B L
TM
Ferraz
D000172:Acromegaly / Q000188:drug therapy* / Q000209:etiology; D000236:Adenoma / Q000150:complications; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000077465:Cabergoline; D004873:Ergolines / Q000627:therapeutic use*; D005147:Facial Bones / Q000187:drug effects*; D005260:Female; D005359:Fibrous Dysplasia, Polyostotic / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000032:analysis / Q000378:metabolism; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D015282:Octreotide / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000150:complications; D012886:Skull / Q000187:drug effects
D018931:Antineoplastic Agents, Hormonal; D004873:Ergolines; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D000077465:Cabergoline; D015282:Octreotide